Tuesday, July 28, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “Oncology” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 10
Total indexed 335
Sponsors 800

Quick answer

Showing 10 pipeline programs matching "Oncology" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

10 results for “Oncology” Back to intelligence hub

Search results

  1. Acoramidis

    BridgeBio Oncology Therapeutics

    Amyloidosis

    phase 3 small molecule active

    3 trials
  2. Infigratinib 0.25 mg/kg/day

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 3 small molecule completed

    1 trial
  3. infigratinib 0.128 mg/kg/day

    BridgeBio Oncology Therapeutics

    Hypochondroplasia

    phase 3 small molecule active

    1 trial
  4. Infigratinib

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 2 small molecule active

    1 trial
  5. Infigratinib 0.016 mg/kg

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 2 small molecule completed

    1 trial
  6. Infigratinib is provided as a single dose of minitablets for oral administration

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 2 small molecule active

    1 trial
  7. Tipifarnib

    Kura Oncology

    HNSCC

    phase 2 small molecule completed

    1 trial
  8. Infigratinib

    BridgeBio Oncology Therapeutics

    Glioma

    phase 1 small molecule terminated

    1 trial
  9. Ziftomenib

    Kura Oncology

    AML

    phase 1 small molecule active

    1 trial
  10. OCT

    Cardiff Oncology

    AMD

    other active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 335 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.